Personalized Medicine in Oncology Partnering Terms and Agreements:Industry Analysis Report @ http://www.researchmoz.us/personalized-medicine-in-oncology-partnering-terms-and-agreements-report.html

1. Personalized Medicine in Oncology Partnering Terms and Agreements
The Personalized Medicine in Oncology Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the
personalized medicine in oncology partnering agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding
and analysis of how and why companies enter personalized medicine in oncology partnering deals. The majority of deals are discovery stage whereby the licensee
obtains a right or an option right to license the licensors personalized medicine technology. These deals tend to be multicomponent, starting with collaborative
R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into
the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the
payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and
databases do not. The initial chapters of this report provide an orientation of personalized medicine in oncology dealmaking and business activities. Chapter 1
provides an introduction to the report, whilst chapter 2 provides an overview of the trends in personalized medicine in oncology dealmaking since 2007, including
details of average headline, upfront, milestone and royalty terms.It also provides the number of deals entered by top 50 big pharma and most active dealmakers in
personalized medicine in oncology partnering. The chapter also includes examples case studies of recent deals in personalized medicine in oncology partnering.
Chapter 3 provides a review of the leading personalized medicine in oncology deals since 2007. Deals are listed by headline value signed by all
biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract. Chapter 4 provides a
comprehensive and detailed review of personalized medicine in oncology partnering deals signed and announced since January 2007. The chapter is organized by
company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), specific therapy focus and specific technology focus.
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract
document on demand. The report also includes adjuvant deals and alliances. The report also includes numerous tables and figures that illustrate the trends and
activities in personalized medicine in oncology partnering and dealmaking since 2007.
In conclusion, this report provides
everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of personalized medicine in oncology
technologies and products. Report scope Personalized Medicine in Oncology Partnering Terms and Agreements is intended to provide the reader with an
in-depth understanding of the personalized medicine in oncology trends and structure of deals entered into by leading companies worldwide. Personalized
Medicine in Oncology Partnering Terms and Agreements includes: Trends in personalized medicine in oncology dealmaking in the biopharma industry since
2007 Analysis of personalized medicine in oncology deal structure Case studies of real-life personalized medicine in oncology deals Access to over 600
personalized medicine in oncology deals The leading personalized medicine in oncology deals by value since 2007 Most active personalized medicine in
oncology dealmakers since 2007 The leading personalized medicine in oncology partnering resources In Personalized Medicine in Oncology Partnering Terms
and Agreements , the available contracts are listed by: Headline value Stage of development at signing Deal component type Specific therapy target Specific
technology target Each deal title links via Weblink to online deal records of actual personalized medicine in oncology partnering deals as disclosed by the deal
parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
table Of Content:
executive Summary
chapter 1 – Introduction
chapter 2 – Trends In Personalized Medicine In Oncology Dealmaking
2.1. Introduction
2.2. Personalized Medicine In Oncology Partnering Over The Years
2.2.1 Biomarker In Oncology Partnering Over The Years
2.2.2 Companion Diagnostic In Oncology Partnering Over The Years
2.2.3 Pharmacogenomics In Oncology Partnering Over The Years
2.3. Big Pharma Personalized Medicine In Oncology Dealmaking Activity
2.3.1 Big Pharma Biomarker, Companion Diagnostic And Pharmacogenomics In Oncology Dealmaking Activity
2.4. Most Active In Personalized Medicine In Oncology
2.5. Personalized Medicine In Oncology Partnering By Deal Type
2.5.1 Biomarker Partnering In Oncology By Deal Type
2.5.2 Companion Diagnostic In Oncology Partnering By Deal Type
2.5.3 Pharmacogenomics In Oncology Partnering By Deal Type
2.6. Personalized Medicine Partnering By Oncology Disease Type
2.6.1 Biomarker Partnering By Oncology Disease Type
2.6.2 Companion Diagnostic Partnering By Disease Type
2.6.3 Pharmacogenomics Partnering By Oncology Disease Type
2.7. Personalized Medicine In Oncology Partnering By Stage Of Development
2.8 Average Deal Terms For Personalized Medicine In Oncology
2.8.1 Personalized Medicine In Oncology Headline Values
2.8.2 Personalized Medicine In Oncology Upfront Payments
2.8.3 Personalized Medicine Milestone Payments
2.8.4 Personalized Medicine In Oncology Royalty Rates
2.9. The Anatomy Of Personalized Medicine In Oncology Partnering
2.9. The Anatomy Of A Personalized Medicine In Oncology Deal
Personalized Medicine in Oncology Partnering Terms and Agreements

2. 2.9.a. Case Study 1: Astrazeneca, Isis Pharmaceuticals- December 07 2012
2.9.b. Case Study 2: Trovagene- Columbia University: December 11, 2011
chapter 3 – Leading Personalized Medicine In Oncology Deals
3.1. Introduction
3.2. Top Personalized Medicine In Oncology Deals By Value
chapter 4 – Big Pharma Personalized Medicine In Oncology Deals
4.1. Introduction
4.2. How To Use Big Pharma Partnering Deals
4.3. Big Pharma Personalized Medicine In Oncology Partnering Company Profiles
abbott
amgen
astellas
astrazeneca
bayer
biogen Idec
boehringer Ingelheim
bristol-myers Squibb
celgene
eisai
eli Lilly
gilead Sciences
glaxosmithkline
johnson & Johnson
merck & Co
merck Kgaa
novartis
pfizer
roche
sanofi
servier
teva
chapter 5 – Personalized Medicine In Oncology Dealmaking Directory
5.1. Introduction
5.2. Company A-z
5.3. By Stage Of Development
discovery
marketed
phase I
phase Ii
phase Iii
preclinical
regulatory
5.4. By Deal Type
asset Purchase
assignment
bigpharma Outlicensing
co-development
collaborative R&d
co-market
contract Service
co-promotion
crada
development
distribution
equity Purchase
evaluation
grant
joint Venture
licensing
manufacturing
marketing
option
Personalized Medicine in Oncology Partnering Terms and Agreements

3. promotion
research
spin Out
sub-license
supply
technology Transfer
termination
5.5. By Oncology Therapy Area
oncology
chapter 6 – Personalized Medicine In Oncology Dealmaking Directory By Specific Technology Type
personalised Medicine
pharmacogenomics
biomarkers
companion Diagnostics
chapter 7 –partnering Resource Center
7.1. Online Personalized Medicine In Oncology Partnering
7.2. Personalized Medicine Partnering Events
7.3. Further Reading On Personalized Medicine Dealmaking
recent Report Titles From Currentpartnering
order Form – Reports
order Form – Therapy Reports
ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your
research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and
across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an
informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
Contact:
M/s Sheela,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-997-4948
Email: sales@researchmoz.us
Website: http://www.researchmoz.us/
Personalized Medicine in Oncology Partnering Terms and Agreements